20 results about "Piperazidine" patented technology

The application discloses a preparation of low-yellowing polyether modified amino silicone oil and a fabric finishing agent containing the same, and relates to amino silicone oil and application thereof. The application uses octamethylcyclotetrasiloxane and 3-piperazinylpropylmethyldimethoxysilane as key raw materials, converts original primary amino groups into secondary amino groups on the basis of traditional amino silicone oil, simultaneously pays attention to control of the molecular mass of the modified amino silicone oil, significantly improves the chemical stability and oxidation resistance of the silicone oil, and secondarily modifies the silicone oil by using allyl epoxy polyether, so that the originally non-hydrophilic amino silicone oil obtains certain hydrophilicity, and the self-emulsifying ability of the silicone oil and the stability of the emulsion are significantly improved. Through the modification, the final silicone oil molecular chain segment can be repeatedly and directionally arranged on the fiber surface in the form of alternating polyether and polysiloxane structure, so that the finishing agent has good hydrophilicity, softness and washability for finishing fabrics.

This invention discloses a piperazine substituted phenol derivative and its applications in pharmaceutical chemistry. The compound, depicted by formula I, exhibits excellent salt formation properties and water solubility, meeting formulation requirements. It also has a low minimum anesthetic effective dose, enabling rapid onset and recovery. This addresses the drawbacks of propofol and ciprofol prodrugs and lipid emulsions. The compound shows promise in developing drugs with sedative, hypnotic, and / or anesthetic effects, as well as in drugs for controlling status epilepticus.

A method for treating pruritus in patients with atopic dermatitis (AD) and / or nodular prurigo (PN) is disclosed, comprising administering a therapeutically effective amount of at least one compound selected from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-carbonyl]-4-methyl-4-[4-(oxecyclobutane-3-yl)piperazin-1-yl]pent-2-enonitrile (rezabrutinib) and pharmaceutically acceptable salts thereof.

The application provides a method for degrading chlorohydrocarbon in water by using illite reinforced ball-milling sulfidation micro zero-valent iron, which comprises the following steps: first, a buffer solution with pH=7 is prepared by using 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, and an oxygen-free aeration treatment is performed; then, illite and S-mZVI bm are mixed to prepare a particle mixture, and the particle mixture is sealed and stored in the buffer solution with pH=7; finally, chlorohydrocarbon pollutants are added into the particle mixture of illite and S-mZVI bm , and a sealed oscillation reaction is performed, so that the concentration of the chlorohydrocarbon in the reaction system is determined. The application directly reinforces the activity of S-mZVI bm material by using illite, which is a clay mineral widely distributed in nature, so that the defects of S-mZVI bm , such as large particle size, slow degradation rate and decreased activity in the later reaction stage, are effectively solved, and the long-term reaction activity of the particles is ensured. The raw materials are green and environmentally friendly, the process is simple, and the materials are easy to obtain.

The application discloses a kind of piperazine derivatives and purposes thereof, and belongs to the field of pharmacy.The piperazine derivatives in the application can improve microglial cell activity, and the compounds have wide application prospects in the preparation of drugs for preventing and treating Alzheimer's disease.

Provided herein are methods of treating sickle cell disease, methods of increasing hemoglobin levels in a subject diagnosed with sickle cell disease, and methods of reducing hemolysis-associated complications in a subject diagnosed with sickle cell disease, together with kits for such treatments, in a subject in need thereof, comprising administering a Gardos channel inhibitor such as 2,2-bis(4-fluorophenyl)-2-phenylacetamide and a pyruvate kinase activator such as N-(4-((4-(Cyclopropylmethyl)-1-piperazinyl)carbonyl)phenyl)-8- quinolinesulfonamide to the subject. Subjects eligible for treatment include subjects as having hemolysis dominant (HD) sickle cell disease on the basis of laboratory markers, clinical history, and / or sequelae.

The application relates to the technical field of synthesis, and particularly discloses a preparation method of a levocetirizine hydrochloride intermediate. The method comprises the following steps: 4-chlorobenzophenone and anhydrous piperazine are subjected to a reductive amination reaction in an organic solvent containing a catalyst to obtain 1-[(4-chlorophenyl)benzyl]piperazine; the 1-[(4-chlorophenyl)benzyl]piperazine is subjected to resolution in an organic solvent by using L-di-p-methylbenzoyl tartaric acid as a resolution agent, and then is subjected to isolation under alkaline conditions to obtain a levocetirizine hydrochloride intermediate (R)-1-[(4-chlorophenyl)benzyl]piperazine. The raw materials and auxiliary materials used in the application are easy to obtain, a novel, efficient and green process route is developed, the whole reaction route is short and simple to operate, the obtained levocetirizine hydrochloride intermediate (R)-1-[(4-chlorophenyl)benzyl]piperazine has high yield, the total yield reaches up to 40% calculated from 4-chlorobenzophenone, and the industrialized production can be realized.

The application discloses a synthesis method of phosphorodiamidate morpholino oligonucleotide, belongs to the technical field of solid-phase synthesis of phosphorodiamidate morpholino oligonucleotide, and specifically relates to the following steps: adding 9-fluorenylmethyloxycarbonyl-piperazine-succinic acid into Wang resin to mix and react to synthesize 9-fluorenylmethyloxycarbonyl-piperazine-succinic acid-Wang resin, then adding phosphoramidite monomers to perform coupling reaction after deprotection treatment, performing cap treatment after the coupling is completed, then repeatedly performing deprotection treatment, coupling reaction and cap treatment until the coupling of all phosphoramidite monomers is completed, then removing the protecting group of the last phosphoramidite monomer, and then performing cleavage treatment and deprotection treatment of a base protecting group to obtain a phosphorodiamidate morpholino oligonucleotide (PMO) reaction solution. The application provides a synthesis method of phosphorodiamidate morpholino oligonucleotide with high coupling efficiency, low impurity level, high yield and high purity.

The present application belongs to the field of textile finishing, and particularly relates to a kind of multi-quaternary ammonium salt textile antibacterial agent with wrinkle resistance function and a preparation method thereof.Cyanuric chloride is reacted with anhydrous piperazine to obtain 2,4,6-tripiperazinyl-s-triazine, then 2,4,6-tripiperazinyl-s-triazine is reacted with chlorobenzene to synthesize 2,4,6-tris(4-benzylpiperazine-1-yl)-1,3,5-triazine, then the quaternary ammonium salt is prepared by reacting with halogenated alkane, finally hydrochloric acid is added to form a salt, and the multi-quaternary ammonium salt textile antibacterial agent with wrinkle resistance function is prepared.The antibacterial agent contains nine nitrogen atoms, multiple quaternary ammonium salts, multiple tertiary amine hydrochlorides, and groups that can couple with fibers, so the molecular bonding with fibers has high firmness, the overall cation density is high, thereby enhancing the antibacterial activity and antibacterial durability.Meanwhile, the molecule has a large skeletal structure extending in the s-triazine direction with triazine ring as the center, which not only imparts excellent antibacterial properties to the fabric, but also improves its wrinkle resistance and dimensional stability.

The application discloses a novel dental nanocomposite material and a preparation method and application thereof, and the nanocomposite material comprises the following preparation raw materials in parts by weight: 15-30 parts of eucommia ulmoides derived antibacterial carbon dots-epigallocatechin gallate, 10-25 parts of iron nitrate, 5-7 parts of boric acid, 8-12 parts of metformin hydrochloride, 4-6.6 parts of zinc chloride, 40-60 parts of hyaluronic acid and 4-6 parts of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid sodium. The application takes eucommia ulmoides derived antibacterial carbon dots-epigallocatechin gallate as a core, and through the o-benzenetriol structure of epigallocatechin gallate, a stable metal-phenol / boric acid ester hybrid network inner shell is cooperatively constructed with iron ions and boric acid, and the effect of synergistically improving anti-inflammatory and long-acting promotion of directional differentiation of dental pulp stem cells is achieved.

The present invention provides a catalyst for an addition reaction of alkylene oxide, the catalyst comprises a nanocomposite ion-exchange resin having a structural formula of P-Im+-M−, wherein P is a nanocomposite resin matrix, Im+ is a cation derived from 5-6 membered heterocycle containing at least one nitrogen atom such as imidazolium cation, pyrazolium cation, pyrrolidinium cation, piperidinium cation, piperazinium cation, pyrimidinium cation, pyrazinium cation, pyridazinium cation, triazinium cation, and M− is an anion. The catalyst of the present invention can be used in the addition reaction of alkylene oxide and carbon dioxide. The catalyst has high wear resistance, high swelling resistance, and high activity. The products after the reaction are easy to separate, and the catalyst can be used continuously many times.

Disclosed are a gastroretentive double-layer sustained-release tablet, a preparation method therefor, and use thereof. An active ingredient of the gastroretentive double-layer sustained-release tablet is 3-[4-[4-(lH-benzotriazol-1-yl)butyl]piperazin-1-yl]benzisothiazole hydrochloride. Said tablet consists of two drug release layers comprising an immediate-release layer and a sustained-release layer. The immediate-release layer comprises the active ingredient, a filler I, and a disintegrant, and the sustained-release layer comprises the active ingredient, a filler II, a swelling material, a release blocker, a swelling enhancer, and a stabilizer. Said tablet can prolong the in vivo absorption window of the drug, maintain the plasma concentration, and prolong the in vivo half-life of the active ingredient.

This invention discloses a wide-bandgap perovskite solar cell modified with an organic passivation layer and its fabrication method. The wide-bandgap perovskite solar cell of this invention comprises, from bottom to top, an anode substrate, a hole-selective contact layer, a perovskite layer, an organic passivation layer, an electron transport layer, a cathode modification layer, and a cathode, stacked sequentially. The organic passivation layer comprises 2-(piperazine-1-yl)ethylamine hydroiodate. This invention effectively passivates perovskite surface defects and also reduces the energy level difference between the perovskite layer and the electron transport layer, promoting selective electron extraction and suppressing interface charge accumulation, while simultaneously improving photovoltaic performance parameters such as open-circuit voltage, fill factor, and photoelectric conversion efficiency. The fabrication process of this invention is simple and suitable for further performance enhancement and large-scale industrial production of perovskite devices.

The application relates to the technical field of protective fabrics, and particularly discloses a preparation method of a flame-retardant and anti-static composite fabric, which comprises the following steps: step (1), 2-(4-aminophenyl)-5-aminobenzimidazole, 1,4-bis(3-aminopropyl)piperazine and 1,2,3,4-cyclobutanetetracarboxylic dianhydride are added into an organic solvent, and polyamide acid solution is obtained through polycondensation reaction at 20-60 DEG C for 2-8 h; step (2), polyether amine, boron lanthanide, a flame retardant, an anti-static agent and a dehydrating agent are added into the polyamide acid solution, and the mixture is stirred and reacted at 35-70 DEG C for 8-16 h to obtain a polyimide solution; and step (3), the polyimide solution is prepared into fibers through a spinning method, and the fibers are subjected to spinning and weaving processes to obtain the flame-retardant and anti-static composite fabric; the preparation method is simple in steps, low in cost and suitable for industrialized production; and the obtained fabric has excellent flame-retardant, anti-static and mechanical properties and has a wide market prospect.